Sensus Healthcare, Inc. reported revenue of $11.7 million for the nine months ended September 30, 2026, down 48.0%, and a net loss of $12.9 million. Cash fell to $12.9 million from $22.1 million, with no borrowings outstanding.
SRTS · Sensus Healthcare, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $2.36
- Open
- $2.30
- Day range
- $2.30–2.51
- 52-week closing range
- $2.26–5.30
- Average volume, 30 days
- 404K
- Short interest
- 222K · 1.4% of shares · 7.2 days
- Short volume, last session
- 38%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 13
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Sensus Healthcare, Inc. reported third-quarter revenue of $6 million, down from $6.9 million, while shipments rose to 26 systems from 16 and gross margin improved to approximately 55% from 39%; adjusted EBITDA was negative $1.5 million versus negative $2.4 million.
Sensus Healthcare reported third-quarter 2026 revenue of $6.0 million, down from $6.9 million, while gross margin improved to 55% from 39.1%. It shipped 26 systems and posted a net loss of $1.5 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Shipments increased to 26 systems, gross margin expanded to 55%, and adjusted EBITDA improved, while third-quarter revenue and net loss declined. Cash also fell, nine-month losses widened, and some shipment revenue was deferred under Fair Deal and rental arrangements.
- + Shipments increased year-over-year to 26 systems from 16.
- + Gross profit increased to $3.3 million from $2.7 million, and gross margin improved to 55% from 39.1%.
- + Adjusted EBITDA improved to negative $1.5 million from negative $2.4 million.
- + The company secured initial system purchases from two large private equity-backed dermatology groups.
- + The company subsequently placed its 1,000th SRT system.
- + Management expects the CMS-proposed 26% increase to take effect in 2027.
- − Third-quarter revenue declined 13.0% to $6.0 million from $6.9 million.
- − Third-quarter net loss widened to $1.5 million, or $0.09 per share, from $0.9 million, or $0.06 per share.
- − Cash, restricted cash and cash equivalents declined to $12.9 million from $15.2 million at June 30, 2026.
- − General and administrative expense increased 21.1% to $2.3 million from $1.9 million.
- − Revenue from three systems shipped under the Fair Deal Agreement program and rental arrangements was deferred over the agreement terms.
- − Nine-month net loss increased to $12.868 million from $4.552 million.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Overall gross profit percentage | 55% | the three months ended September 30, 2026 filing | — |
|
|
|||
| Systems shipped under Fair Deal Agreement and rental arrangements | 3 | the three months ended September 30, 2026 filing | — |
| Adjusted EBITDA, non-GAAP non-GAAP | -8.69M | Nine Months Ended September 30, 2026 | — |
| Unit shipments | 26 | third quarter of 2026 | — |
| Active website users | 153% | Q2 2026 | — |
| Adjusted EBITDA non-GAAP | $3M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -8.75M
+86K Depreciation
+70K Stock compensation expense
+5.69M Income tax expense (benefit)
-117K Interest income, net
= Adjusted EBITDA -3.02M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRTS
this stock
Sensus Healthcare, Inc.
|
$38.85M | -40.7% | -34.3% | — | 1.4% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 14
Sensus Healthcare, Inc. reported revenue of $11.7 million for the nine months ended September 30, 2026, down 48.0%, and a net loss of $12.9 million. Cash fell to $12.9 million from $22.1 million, with no borrowings outstanding.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRTS | -26.7% | -17.8% | -17.2% | -14.5% | -40.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -21.3% | -11.5% | -11.6% | -9.2% | -45.7% |